NEOLEUKIN THERAPEUTICS INC NLTX 深 滬
交易中 09-20 13:52:09 美东时间
3.49
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 3.49
- 總市值 3073.05万
- 52周最高 18.80
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 8.30
- 委 比 0.00%
- 總股本 880.53万
- 歷史最高 362.60
- 量 比 0
- 振 幅 0.00%
- 歷史最低 7.50
- 每 手 1
- 風險率 1.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Neurogene a new outperform at Baird on gene therapy for Rett syndrome
Baird started Neurogene (NASDAQ:NGNE) off at outperform as its Rett syndrome candidate, NGN-401, has shown promise with early data and the asset was recently selected by the U.S. FDA for a pilot progr...
06-11 23:02
Neoleukin Therapeutics GAAP EPS of -$1.00 beats by $0.03
Neoleukin Therapeutics press release (NASDAQ:NGNE): Q1 GAAP EPS of -$1.00 beats by $0.03. Cash, cash equivalents and investments as of March 31, 2024 were $169.5 million. The Company expects current c...
05-10 19:46
89bio Appoints Biotech Industry Veteran, Martin Babler to Its Board of Directors
SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasd...
04-18 04:05
Neoleukin Therapeutics Plans 1-For-5 Reverse Stock Split
The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023.
2023-09-22 20:03
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers TRACON Pharma (NASDAQ:TCON) stock moved upwards by 26.8% to $0.26 duri...
2023-08-18 05:32
Moore Kuehn Encourages PRDS, AMNB, NLTX, and SCU Investors to Contact Law Firm
NEW YORK, Aug. 3, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims con...
2023-08-04 03:15
UnitedHealth Has A Large Runway Of Growth, 'Very Attractive Valuation,' Says Bullish Analyst
UnitedHealth Group Inc (NYSE: UNH) announced its second-quarter earnings on Friday, lending upside to shares.
2023-07-18 23:09
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, NLTX, FREQ
NEW YORK, July 18, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
2023-07-18 22:39
Mizuho Maintains Neutral on Neoleukin Therapeutics, Lowers Price Target to $1.5
Mizuho analyst Mara Goldstein maintains Neoleukin Therapeutics (NASDAQ:NLTX) with a Neutral and lowers the price target from $2 to $1.5.
2023-05-09 22:04
